Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
1.870
+0.010 (0.54%)
At close: Aug 14, 2026, 4:00 PM EDT
1.858
-0.012 (-0.65%)
After-hours: Aug 14, 2026, 5:55 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,308,760
Market Cap
5.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| GeoVax Labs | 19 |
| Cardio Diagnostics Holdings | 17 |
| BioRestorative Therapies | 14 |
| Ensysce Biosciences | 10 |
| Ernexa Therapeutics | 7 |
| Enveric Biosciences | 6 |
| Addex Therapeutics | 3 |
CVKD News
- 1 day ago - Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process - GlobeNewsWire
- 1 day ago - Cadrenal Therapeutics Quarterly report: Q2 2026 - Filings
- 1 day ago - Cadrenal Therapeutics Earnings release: Q2 2026 - Filings
- 11 days ago - Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation - GlobeNewsWire
- 11 days ago - Cadrenal Therapeutics Proxy statement: Proxy filing - Filings
- 11 days ago - Cadrenal Therapeutics Proxy statement: Proxy filing - Filings
- 22 days ago - Cadrenal Therapeutics Proxy statement: Proxy filing - Filings
- 24 days ago - Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation - GlobeNewsWire